The Valley Desk

NCT02658981 · Interventional trial

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Overall registry status Completed

Phase 1

Conditions Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov